Loxapine succinate
Loxapine succinate structure
|
Common Name | Loxapine succinate | ||
|---|---|---|---|---|
| CAS Number | 27833-64-3 | Molecular Weight | 445.896 | |
| Density | N/A | Boiling Point | 458.6ºC at 760mmHg | |
| Molecular Formula | C22H24ClN3O5 | Melting Point | 150-152°C | |
| MSDS | Chinese USA | Flash Point | 231.1ºC | |
|
Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC–MS/MS
J. Pharm. Biomed. Anal. 58 , 83-93, (2012) Loxapine represents an interesting example of old “new” drug and is recently drawing attention for its novel inhalation formulation for the treatment of both psychiatric and non-psychiatric disorders. It is extensively metabolized to several active metabolite... |
|
|
In vitro aerosol characterization of Staccato(®) Loxapine.
Int. J. Pharm. 403(1-2) , 101-8, (2011) Medicinal aerosol products (metered dose and dry powder inhalers) require characterization testing over a wide range of use and pre-operating stress scenarios in order to ensure robust product performance and support submissions for regulatory approval. Aeros... |
|
|
Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Int. J. Clin. Pract. 66(3) , 318-25, (2012) To describe the efficacy of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder using different examples of effect size (ES).Psychopharmacologic Drug Advisory Committee briefing documents as prepared by the produc... |
|
|
The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.
Can. J. Psychiatry. 56(10) , 630-4, (2011) To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009.Analyses were performed on IMS Brogan's Canadian Disease and Therapeutic Index (CDTI). The CDTI is a national physician panel study con... |
|
|
Interaction of clozapine and its nitrenium ion with rat D2 dopamine receptors: in vitro binding and computational study.
J. Comput. Aided Mol. Des. 25(2) , 163-9, (2011) The interaction of diazepine analogues like clozapine or olanzapine with D2 receptor was greatly affected by a mixture of HRP/H(2)O(2) known to induce the formation of nitrenium ion. Unlike diazepine derivatives, the oxidative mixture had low impact on the af... |
|
|
The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2).
J. Pharmacol. Exp. Ther. 340(3) , 706-15, (2012) Sodium-activated potassium (K(Na)) channels have been suggested to set the resting potential, to modulate slow after-hyperpolarizations, and to control bursting behavior or spike frequency adaptation (Trends Neurosci 28:422-428, 2005). One of the genes that e... |
|
|
In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine.
Biopharm. Drug Dispos. 32(7) , 398-407, (2011) In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) enzymes responsible for the oxidative metabolism of loxapine to 8-hydroxyloxapine, 7-hydroxyloxapine, N-desmethylloxapine (amoxapine) and loxapine N-oxide. These studies included us... |
|
|
Now take a deep breath: inhaled loxapine for the treatment of acute agitation.
J. Psychosoc. Nurs. Ment. Health Serv. 50(1) , 16-8, (2012) Acute agitation in patients with schizophrenia or bipolar disorder is an important clinical management problem. Liquid concentrates, orally disintegrating tablets, and/or intramuscular formulations of several second-generation atypical antipsychotic drugs are... |
|
|
Validation of HPLC-MS/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma.
Bioanalysis 2(12) , 1989-2000, (2010) Two ESI-LC-MS/MS methods were validated for the quantitative analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human K(2)EDTA plasma. Cation-exchange solid-phase extraction (SPE) was used to extract loxapine, amoxapine and ... |
|
|
Neuroleptic malignant syndrome-like reaction precipitated by antipsychotics in a patient with gamma-butyrolactone withdrawal.
J. Addict. Med. 5(4) , 302-3, (2011) We report the case of a patient with chronic abuse of gamma-butyrolactone (GBL, 3 bottles per week for 4 months), who in the course of the management of acute agitation and hallucinations developed symptoms compatible with both neuroleptic malignant syndrome ... |